PT-141

PT-141 (Bremelanotide) is a melanocortin agonist. The HEIVE catalog describes it as: FDA-approved for hypoactive sexual desire disorder in premenopausal women; acts centrally, not vascularly. It is also known as Bremelanotide and Vyleesi.

HEIVE groups PT-141 under erectile function and libido. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

Yes, for a specific product and indication. Vyleesi (bremelanotide) is indicated for acquired, generalized hypoactive sexual desire disorder in premenopausal women, subject to label exclusions. It is not indicated for men, postmenopausal women or sexual-performance enhancement. Approval of a labeled medicine does not approve an arbitrary research or compounded product containing the same ingredient.

• FDA product data (October 6, 2026)
• Vyleesi prescribing information

The HEIVE editorial risk summary for PT-141 lists: Nausea in roughly 40% of trial subjects; flushing; headache. Longer-term concerns: Blood-pressure elevation. Not for uncontrolled hypertension. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

PT-141 has no single onset time established by this catalog. The editorial timeline starts with “First dose · 2–8 hours”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for PT-141: 1.75 mg subcutaneously, 45 minutes before, max 8 doses monthly. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies PT-141 as having human research. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists a nasal form for PT-141. A listed form is not evidence of an approved or effective treatment. Nasal forms are listed in the source catalog; this does not establish approval, efficacy or equivalent absorption. HEIVE injection calculations do not apply to nasal forms.

Preparation of PT-141 depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for PT-141 depends on the specific formulation (injectable and nasal in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for PT-141: Use is episodic by design; no tolerance pattern described. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

PT-141 and Kisspeptin-10 share the catalog categories libido and erectile function. PT-141: FDA-approved for hypoactive sexual desire disorder in premenopausal women; acts centrally, not vascularly. Kisspeptin-10: The upstream switch of the reproductive axis. It signals the hypothalamus to release GnRH — one step earlier than anything else here acts. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View Kisspeptin-10

The HEIVE editorial summary highlights: Some trial participants reported mood lift entirely separate from the sexual endpoint. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.